- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Waltham Today
By the People, for the People
Spyre Therapeutics Announces $403M Public Offering
Biotech firm raises funds to advance pipeline of IBD and immune-mediated disease treatments.
Apr. 15, 2026 at 3:00am
Got story updates? Submit your updates here. ›
Spyre Therapeutics' $403 million public stock offering taps into the institutional machinery of global finance to fund the biotech firm's pipeline of next-generation immune disease treatments.Waltham TodaySpyre Therapeutics, a clinical-stage biotech company, announced the pricing of a $403 million public offering of 6.5 million shares of common stock at $62 per share. The company also granted underwriters an option to purchase up to an additional $60.5 million in shares. The offering is expected to close on April 16, 2026, subject to customary closing conditions.
Why it matters
The funds raised will allow Spyre to advance its pipeline of investigational antibody therapies targeting inflammatory bowel disease (IBD) and other immune-mediated diseases, which represent a significant unmet medical need. As a clinical-stage biotech, this public offering provides Spyre with the capital needed to progress its lead candidates through further development and clinical trials.
The details
Spyre Therapeutics is a clinical-stage biotech company focused on developing next-generation treatments for IBD and other immune-mediated diseases. Its pipeline includes investigational extended half-life antibodies targeting a4p7, TL1A, and IL-23. The company says the $403 million in gross proceeds from the public offering will be used to advance its clinical programs.
- The offering is expected to close on or about April 16, 2026.
- Spyre filed a registration statement for the offering on February 27, 2026.
The players
Spyre Therapeutics, Inc.
A clinical-stage biotechnology company advancing antibody engineering, dose optimization, and therapeutic combinations for the treatment of inflammatory bowel disease and other immune-mediated diseases.
Jefferies LLC
One of the joint book-running managers for Spyre's public offering.
Goldman Sachs & Co. LLC
One of the joint book-running managers for Spyre's public offering.
Evercore ISI
One of the joint book-running managers for Spyre's public offering.
Guggenheim Securities, LLC
One of the joint book-running managers for Spyre's public offering.
What’s next
The offering is expected to close on or about April 16, 2026, subject to satisfaction of customary closing conditions.
The takeaway
Spyre Therapeutics' successful $403 million public offering provides the clinical-stage biotech company with the capital needed to advance its pipeline of investigational antibody therapies for inflammatory bowel disease and other immune-mediated diseases, which represent a significant market opportunity.
